Vaccine maker Novavax on Wednesday reported fourth-quarter revenue and earnings that missed Wall Street's estimates and reiterated plans to cut costs as it fights to stay afloat. Still, Novavax narrowed its losses in the quarter from the same period a year ago, even as demand for the biotech company's Covid vaccine – its only marketable product – and other products that combat the virus continue to plummet worldwide. Here's what Novavax reported for the fourth quarter compared with what Wall Street was expe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26770 NOVAVAX, INC. (Exact name of Registrant as specified in its charter) Delaware 22-2816046 (State of incorporation) (I.R.S. ...

Many investors have seen Novavax (NVAX 3.97%) as a promising recovery story ever since the biotech launched a plan to cut costs to better match the revenue opportunities ahead of it. Once one of the biggest coronavirus vaccine hopefuls, Novavax's shares soared by more than 2,700% in 2020 -- then plummeted as the development and commercialization of the company's COVID vaccine candidate lagged behind its rivals.The late arrival of Novavax's vaccine on the market meant the company missed out on the early mult ...

Novavax (NVAX) shares rallied 8.4% in the last trading session to close at $5.29. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19% gain over the past four weeks.Share price rose after the company announced that it has reached a settlement with Gavi Vaccine Alliance over an advance purchase agreement signed in 2021 between the two parties. Per the settlement terms, Novavax has made an upfront payment of $75 ...

Novavax (NASDAQ:NVAX) stock is taking off on Thursday after the company reached a settlement with global vaccine organization Gavi.This settlement has Novavax agreeing to pay up to $475 million to Gavi following a dispute over payments for its Covid-19 vaccine. The crux of the matter had to do with Gavi seeking a refund on a $700 million advance payment for vaccines it later chose not to order from Novavax.Novavax isn’t paying Gavi back all at once and will instead make payments through Dec. 31, 2028. This ...

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.Novavax on Thursday said it will settle a bitter arbitration dispute with Gavi, a nongovernmental global vaccine organization, over a canceled Covid vaccine purchase agreement. Novavax could pay up to $475 million to the organization, but the total amount may be less if Gavi decides to order more shots from the cash-strapped c ...

It's official: The S&P 500 is in a bull market after reaching a new all-time high last month. The index actually has been in this positive market phase ever since it started recovering from its bear market low about 16 months ago -- and since bull markets generally last longer than bear markets, investors should have plenty of time to benefit from this one.How to get the most out of a bull market? By investing in stocks with solid growth prospects. That's because these environments usually support growth co ...

GAITHERSBURG, Md. and GENEVA, Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373). This agreement brings the pending arbitration related to the APA to a close. "Novavax is pleased to have reached this agreement with Gavi as it gives us the ability to continue to work together toward our shared mission of ensuri ...

GAITHERSBURG, Md., Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Wednesday, February 28, 2024. Details of the event and replay are as follows:Conference call details: Date: February 28, 2024 Time: 8:30 a.m. U.S. EST URL to register phone: https://emportal.ink/3 ...

After a brutal three-year period that saw its shares collapse by 99%, any remaining longtime shareholders of Novavax (NVAX 5.13%) are doubtlessly eager for the biotech to finally step out of the shadows of its first "success" and launch its next winner, even if it means waiting as long as 10 years.Alas, that might not be enough time for this company to find its next big thing. In fact, it might not survive half that long. Here's why.Will it even be around?There is a strong possibility that Novavax won't eve ...